top of page

OZ mrs log.jpg

Metastasis Publications

Highlighting 2024/2025's metastasis publications

Circulating immune cells exhibit distinct traits linked to metastatic burden in breast cancer
Mangiola S, Brown R, Zhan C, Berthelet J, Guleria S, Liyanage C, Ostrouska S, Wilcox J, Merdas M, Fuge-Larsen P, Bell C, Schröder J, Mielke LA, Mariadason JM, Tsao SC, Chen Y, Yadav VK, Vodala S, Anderson RL, Merino D, Behren A, Yeo B, Papenfuss AT, Pal B.Breast Cancer Res. 2025 May 8;27(1):73. doi: 10.1186/s13058-025-01982-2. PMID: 40340807; PMCID: PMC12063295.

Inhibitor of DNA binding-1 is a key regulator of cancer cell vasculogenic mimicry
Thompson EJ, Dorward EL, Jurrius K, Nataren N, Tondl M, Myo Min KK, Cockshell MP, Fouladzadeh A, Toubia J, DeNichilo M, Merino D, Bonder CS.
Mol Oncol. 2025 Mar 21. doi: 10.1002/1878-0261.70027.
PMID: 40116596

EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.
Piper AK, Penney C, Holliday J, Tincknell G, Ma Y, Napaki S, Pantel K, Brungs D, Ranson M.
Int J Mol Sci. 2024 May 20;25(10):5565. doi: 10.3390/ijms25105565.
PMID: 38791602; PMCID: PMC11122469.

B7-H3 Expression in Breast Cancer and Brain Metastasis.
Joshi V, Beecher K, Lim M, Stacey A, Feng Y, Jat PS, Duijf PHG, Simpson PT, Lakhani SR, McCart Reed AE
Int J Mol Sci. 2024 Apr 3;25(7):3976. doi: 10.3390/ijms25073976.
PMID: 38612786; PMCID: PMC11012592.

Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism.
Filipe EC, Velayuthar S, Philp A, Nobis M, Latham SL, Parker AL, Murphy KJ, Wyllie K, Major GS, Contreras O, Mok ETY, Enriquez RF, McGowan S, Feher K, Quek LE, Hancock SE, Yam M, Tran E, Setargew YFI, Skhinas JN, Chitty JL, Phimmachanh M, Han JZR, Cadell AL, Papanicolaou M, Mahmodi H, Kiedik B, Junankar S, Ross SE, Lam N, Coulson R, Yang J, Zaratzian A, Da Silva AM, Tayao M, Chin IL, Cazet A, Kansara M, Segara D, Parker A, Hoy AJ, Harvey RP, Bogdanovic O, Timpson P, Croucher DR, Lim E, Swarbrick A, Holst J, Turner N, Choi YS, Kabakova IV, Philp A, Cox TR.
Adv Sci (Weinh). 2024 Apr 11:e2307963. doi: 10.1002/advs.202307963.
Epub ahead of print. PMID: 38602451.

Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy.
Kelly TE, Spillane CL, Ward MP, Hokamp K, Huang Y, Tewari P, Martin CM, Norris LA, Mohamed BM, Bates M, Brooks R, Selemidis S, Brooks DA, Kamran W, Saadeh FA, O'Toole SA, O'Leary JJ.
Front Cell Dev Biol. 2023 Dec 7;11:1150991. doi: 10.3389/fcell.2023.1150991.
PMID: 38143926; PMCID: PMC10740207.

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.
Kim S, Park JM, Park S, Jung E, Ko D, Park M, Seo J, Nam KD, Kang YK, Lee K, Farrand L, Kim YJ, Kim JY, Seo JH.
J Exp Clin Cancer Res. 2023 Nov 4;42(1):292. doi: 10.1186/s13046-023-02866-z.
PMID: 37924112; PMCID: PMC10625208.

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.
Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6.
Epub 2023 Nov 30. PMID: 38043558.

bottom of page